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Background
The expression ‘Patient-Reported Outcomes’ (PROs), which
came into frequent use only in the last decade, refers to ‘any
report coming from patients about a health condition and its
treatment’ (1) as opposed to data provided by other sources
(clinical and instrumental tests, providers and caregivers).
PROs are gaining increasing awareness and emphasis in
clinical research and by regulatory bodies because of their
relevance in the overall treatment efficacy assessment (2, 3).
Among PROs, Health-Related Quality of Life (HRQoL)
and patient-reported symptoms have been extensively evalu-
ated in rhinitis and asthma, but unexplored areas and meth-
odological limits have recently been identified and discussed
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Abstract
The GA2LEN taskforce on Patient-Reported Outcomes (PROs) and Health-Related
Quality of Life (HRQoL) published in 2009 a position paper concerning PROS and
HRQoL assessment in clinical trials on allergy. Because of the specificity of this
topic in asthma and rhinitis, specific recommendations are needed. The aim of this
position paper is to define PROs and their meaning in asthma and rhinitis research,
explore the available tools to provide criteria for a proper choice, identify patient-
related factor which could influence PROs assessment, define specific recommenda-
tions for assessment, analysis and results spreading, underline the unexplored areas
and unmet needs. PROs assessment is gaining increasing importance, and it must
be performed with a rigorous methodological procedure and using validated tools.
This approach enables to better understand patient-related factors influencing
clinical trials and real-life management outcomes, identify patients subgroups that
can benefit from specific treatment and management plan and tailor treatment to
address PROs (not only physician-defined targets) to improve asthma and rhinitis
management.
Abbreviations
HRQoL, Health-Related Quality of Life; MID, Minimal Important
Difference; PROs, Patient-Reported Outcomes.
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(4, 5). Following the consensus reached by the GA2LEN task
force for PROs assessment providing general criteria concern-
ing PROs definition, meaning and methods of evaluation
(e.g. choice of the tool, assessment schedule, results analysis)
in allergic diseases research (6), the aim of this position paper
is to provide a comprehensive collection of specific sugges-
tions and recommendations for a proper PROs investigations
into rhinitis and asthma, especially clinical trials.
Definition and relevance of PROs and PROs influencing
factors in allergic rhinitis and/or asthma
The development of PROs instruments has a long history
dating back to the World Health Organization’s broadened
definition of health as ‘a state of physical, mental, and social
well-being and not merely the absence of disease’ (7). This
statement led to the groundwork for conceptualizing health
as multidimensional and served to draw the attention away
from the disease-centred approach, which emphasizes physio-
logical indices of health, towards a patient-centred approach,
which includes the patient’s viewpoint in evaluating the
impact of an illness. Furthermore, the fundamental role of
patient’s perspectives is now underlined by the GRADE
system (8), which represents the best option in defining the
criteria for grading evidence and developing guidelines. As a
matter of fact, it includes also patients’ preferences and
values as cornerstones in the process of formulating recom-
mendations towards diagnostic and therapeutic interventions,
thus contributing to bring scientific research to real life.
The definition of the most important PROs in scientific
research on patients suffering from asthma and/or rhinitis
with an example of the tools used for their assessment is
reported in Table 1.
Like in other conditions, PROs in patients with asthma
and rhinitis are not only influenced by factors connected to
the disease itself (clinical characteristics, symptoms, severity,
chronicity, comorbidities) or by therapeutical strategies
adopted for their control (i.e. drug and treatment schedules)
but also by variables related to the patient, both to his per-
sonal (age, sex, job, school functioning, race/ethnicity, socio-
demographic characteristics and lifestyle) and psychological
characteristics. Psychological factors could be considered
PROs when they refer to the disease impact on the psycho-
logical factor itself (e.g.: effect of uncontrolled asthma on
mood or emotional and social functioning) (70) or a patient-
related factor influencing PROs when the presence of a psy-
chological characteristic could influence PROs (e.g.: the effect
of depression on asthma) (71).
Table 2 sums up some of the most relevant psychological
patient-related factors influencing PROs and examples of the
most suitable tools to assess them.
Among the variables reported in Table 2, mood disorders
and anxiety, especially for what concerns patients with
asthma, are those which deserved more attention in the respi-
ratory allergy research (72–76). As psychological factors
could influence answering to PRO tools, a proper evaluation
and their introduction among trial’s inclusion/exclusion crite-
ria is suggested.
Available tools for assessing PROs in patients with
rhinitis and/or asthma in clinical trials and criteria for
the choice of the proper tool
For the evaluation of satisfaction, preferences, illness percep-
tion, willingness to pay and adherence, some validated ques-
tionnaires (See Table 1), already used for other diseases as
well, are available. So far, many of them have not been
extensively used in respiratory field, and their use is suggested
for further research.
Health-related quality of life, symptoms and control
assessment deserve particular considerations.
HRQoL assessment
Several validated tools for assessing HRQoL in rhinitis and
asthma are currently available. In the choice of the tool, the
following aspects should be considered:
Disease target
The tool should be suitable for the clinical pattern under
investigation. In particular, specific tools for HRQoL assess-
ment in asthma (12, 77–92), rhino-conjunctivitis (93–96)
rhino-sinusitis (97–99), concomitant asthma and rhinitis (14,
100), specific symptoms related to asthma and rhinitis, such
as cough, (101–103) or specific functional aspects (e.g.
HRQoL in patients with obstructive lung disease) (104–106)
are available.
The impact of conjunctivitis on patients’ life, a phenome-
non often investigated by specific tools for rhinitis, can also
be evaluated through ad hoc questionnaires (107) or validated
tools for specific ocular pathologies (e.g. keratoconjunctivitis)
(108).
Some tools are specifically addressed to investigate the
impact of pathology not on the patient but in his/her care-
giver, while others refer to the child’s HRQoL but are filled
in by caregivers (86, 88, 91).
Population target
The tool should be chosen taking into account the range
of age for which it has been specifically validated. Most of
questionnaires have been developed and validated for adult
patients; nowadays, specific questionnaires which investigate
the obstructive pathology in the lower airways (12, 14, 77–83,
104–106), rhino-conjunctivitis (93, 95, 96, 107), rhino-sinusitis
(97–99) and cough (101–103) in adult population are
available. For the evaluation of HRQoL related to respira-
tory allergy in paediatric population, some tools which inves-
tigate asthma in children (84–88, 90, 92) and adolescents (89,
90), as well as rhino-conjunctivitis (94) and asthma with con-
comitant rhinitis (100), exist.
Methods of administration (self-administered and/or interview/
telephone administered) and format (paper or electronic
version)
In some paediatric tools, the answers are given in the form of
smiley faces (90), and the questionnaires can be filled in with
the caregiver’s help (90–92).
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Table 1 Definition of PROs and examples of validated tools
PRO Definition Examples of tools
Quality of Life (QoL) Individual’s perception of his/her position in life in the context of the
culture and value systems in which he/she lives and in relation to his/
her goals, expectations, standards and concerns. It is a broad-ranging
concept incorporating in a complex way the person’s physical health,
psychological state, level of independence, social relationships,
personal beliefs and their relationship to salient features of the
environment (9)
WHOQOL-100 (10)
Health-Related Quality
of Life (HRQoL)
The impact of the disease and its therapy upon a patient, as perceived
by patient himself (11)
Asthma Quality of Life Ques-
tionnaire – AQLQ(S) (12)
Rhino-conjunctivitis Quality of Life
Questionnaire – RQLQ(S) (13)
RHINASTHMA (14)
Health status The ability of a subject to function in a variety of physical, emotional
and social activities (15, 16)
Medical Outcome Study Short
Form Health Survey (SF-36) (17)
Nottingham Health Profile (18)
Quality-adjusted life year’ (QALY)
(19)
Standard gamble (19, 20)
Time trade-off (20)
Well being An individual’s evaluation of his/her health daily functioning, happiness
and welfare (21)
Psychological General Well-Being
(PGWB) (22)
Satisfaction The cognitive product of the comparison between ideal life and reality
and can therefore be quantitatively measured (23)
Satisfaction Profile (SAT-P) (24)
SATQ (25)
Adherence The extent to which a person’s behaviour, taking medication, following
a diet, and/or executing lifestyle changes, corresponds with agreed
recommendations from a health care provider (26, 27)
Medication Adherence Report
Scale for Asthma (MARS-A) (28)
ASK-20 (29)
Illness perception The personal model or representation of an illness aimed at making
sense and respond to the presence of a disease (30, 31)
Revised Illness Perception
Questionnaire (IPQ-R) (32)
Willingness to pay The maximum value people are willing to pay to attain a service rather
than do without it (21)
Dichotomous (33) or multiple
choices assessment (34) contin-
gent evaluation question (35)
Preferences Action that a patient would choose in a particular medical situation at a
particular time, given a set of alternatives (36)
Clinical Trial Patient Preference
Instrument (37)
Clinical Practice Patient Preference
Instrument (37)
Autonomy Preference Index (38)
Symptoms The subjective experiences about the illness, disease or injury. This
experience is reported but not necessarily observed by anyone other
than the patient (39)
Rhino-conjunctivitis and asthma
symptom score (40)
Visualanaloguescale for rhinitis (41)
Control Asthma: none (twice or less/week) daytime symptoms, none
limitations of activities, none nocturnal symptoms/awakenings, none
(twice or less/week) need for reliever/ rescue treatment, normal lung
function, none exacerbations. (42)
Rhinitis: a definition of controlled rhinitis is not preset in ARIA
guidelines (43). The acronyms SCUAD (severe chronic upper airway
diseases) defines those patients whose symptoms are inadequately
controlled despite adequate (i.e. effective, safe, and acceptable)
pharmacologic treatment based on guidelines (44)
Asthma Control Test (ACT) (45)
Asthma Control Questionnaire
(ACQ) (46)
‘Control of Allergic Rhinitis and
Asthma Test’ (CARAT) (47, 48)
Work productivity Costs associated with production
Loss and replacement costs because of illness, disability and death
of productive persons, both paid and unpaid (49)
Work Productivity and Activity
Impairment (WPAI) (50)
Work Productivity and Activity
Impairment Questionnaire –
Allergy Specific (WPAI-AS) (51)
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A parameter to be considered when choosing a tool is also
the number of items. It ranges from less than 20 items (88) to
more than 70 (87, 106). Some tools, in addition to the entire
version, are also available in a validated shortened version
(96, 99, 109, 110).
Availability of a validated version of the tool in the studied
population’s language
Most of the tools are developed and validated in English
(UK, USA, Canada, Australia), but others have originally
been developed in German (87, 104, 105) and Italian (14, 101,
108). For some tools (e.g. 14, 78, 80–82, 92–97, 107), valida-
tion in languages different from the original is available.
Investigated dimensions
The different questionnaires, despite being specific for the
same disease, are not interchangeable. Actually, they analyse
different aspects of the same disease and, therefore, they pro-
vide information on different dimensions of subjectivity. For
example, some questionnaires have a specific domain for sex-
ual life (77, 104), others for sport (77), others for sleeping
(77, 93, 95, 107). Therefore, the tools must be selected to
match the objective of the study.
Scaling and scoring system
Tools differ for scaling and scoring system. Although it is not
a major reason to choose an instrument, it should be known
and taken into account both during the choice phase (i.e. to
avoid the floor and ceiling effect and potential difficulties when
filling in a questionnaire) and for a correct result analysis.
Most tools use a 3-point (77, 108), 4-point (84, 85, 87, 99),
5-point (14, 78, 82, 85, 86, 88, 90, 97, 101), 6-point (98, 107)
or 7-point (81, 89, 91, 92, 96, 100, 102, 104, 105) Likert scale,
dichotomous items (79) or a combination of a Likert scale
and dichotomous items (106).
The tools also differ in the scoring system, which can
include the score standardization at 100 (14, 78, 86, 88, 101,
106–108), the addition of the total score and/or the single
Table 2 Definition of patient-related factors that influence PROs and examples of validated tools
Patient-related
factors that
influence PROs Definition Examples of tools
Alexithymia Cluster of characteristics implying difficulties in identifying and expressing
feelings, an absence of fantasy and a concrete, externally oriented thinking
style, and also difficulties differentiating between emotions and bodily
sensations (52)
Toronto Alexithymia Scale (TAS-20)
(53, 54)
Coping Coping strategies refer to the specific efforts, both behavioural and
psychological, that people employ to master, tolerate, reduce, or minimize
stressful events (55)
Coping Orientations to Problem
Experienced (COPE) (56)
Coping with a Disease (CODI) (57)
Locus of control Generalized belief regarding the extent to which life outcomes are controlled
by an individual’s actions (internal control) or by external forces such as luck,
fate or other individuals (external control) (58)
Multidimensional health locus of
control (MHLC) (59)
Rotter’s 29-item Locus of Control
(58, 60)
Personality A dynamic organization, inside the person, of psychophysical systems that
create a person’s characteristic patterns of behaviour, thoughts and feelings
(61)
Minnesota multiphasic personality
inventory – 2 (62)
Big Five Inventory Personality Test
(63)
Mood disorders The term given for a group of diagnoses in the Diagnostic and Statistical
Manual of Mental Disorders (DSM IV TR) classification system where a
disturbance in the person’s mood is hypothesized to be the main underlying
feature (64)
Beck Depression Inventory (BDI)
(65)
Hospital Anxiety and Depression
Scale (HADS) (66)
Anxiety disorders A blanket term covering several different forms of abnormal and pathological
fear and anxiety (64)
State-Trait Anxiety Inventory (67)
Hospital Anxiety and Depression
Scale (HADS) (66)
Stress The response of the body to any demand.
The term distress is used for the consequences of the failure to respond
appropriately to emotional or physical threats to the organism.
It includes a state of alarm and adrenaline production, short-term resistance
as a coping mechanism and exhaustion.
Common stress symptoms include irritability, muscular tension, inability to
concentrate and a variety of physical reactions (68)
POMS (69)
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domains (79, 85, 87, 89, 93, 97, 98, 102–105) and mean scores
(12, 77, 81, 84, 91–96, 99, 100), the multiplication by a
constant factor (82).
For some questionnaires, the paper which describes the
validation process does not provide information concerning
the scoring calculation instructions (80, 83, 90).
The minimal important difference (MID) is an important
parameter for determining sample sizes and for interpreting
statistically significant PRO results in clinical trials. It was
defined as the smallest change in an outcome measure
perceived as beneficial by patients or physicians, which leads
to a change in the patient’s management, assuming minimal
toxicity and cost (111, 112). MID is available for some
HRQoL questionnaires (e.g. 80, 81, 92–94, 107), but it is
important to remember that the MID may vary by popula-
tion and context, and no one MID may be considered valid
for all study applications involving a PRO instrument.
Responsiveness (the ability of the questionnaire to detect sig-
nificant differences over time in patients whose status has
changed) (113) and MID must be demonstrated and docu-
mented for the particular study population (114, 115).
Symptoms assessment
Both asthma and rhinitis symptoms are extensively assessed
in clinical trials through the use of symptoms scores that
have never undergone validation process. Therefore, the use
of tools whose validity, responsiveness and reliability have
been evaluated (40, 41) should be encouraged.
When the PROs assessment is carried out using a symp-
tom score (i.e. T4SS, T5SS, asthma symptoms score), the rea-
sons for the choice should be declared in the study methods.
Disease control assessment
Control assessment is possible in asthma through different
validated tools, whose characteristics do not make them
interchangeable. For instance, the Asthma Control Test
(ACT) (45), the Asthma Control Questionnaire (ACQ) (46)
and the Lara Asthma Symptom Scale (LASS) (116) all
provide a control level measurement, but while ACT and
LASS only require patient’s subjective evaluations, ACQ, in
its original version, combines subjective symptoms, bron-
chodilator use and percentage of predicted FEV1. The
Asthma Control Scoring System (ACSS) (117) also combines
a clinical score (self-reported by the patient), functional data
(which include PEF, FEV1 and delta PEF) and an inflamma-
tory score (% sputum eosinophilia).
In children and adolescents, the efficacy of the treatment
in inducing control can be assessed also with the Asthma
Therapy Assessment Questionnaire (ATAQ) (118), which
explores the symptoms control, behaviour and attitude barri-
ers, self-efficacy barriers and communication gaps.
A paper describing the development process of the
Control of Allergic Rhinitis and Asthma Test (CARAT)
for the control evaluation in patients with asthma and
rhinitis has been recently published (47, 48). Additional
studies that provide data about the psychometric properties
of the questionnaire and its applicability in clinical trials
are needed.
Methodological issues for PROs evaluation in rhinitis and
asthma clinical trials
The evidence-based medicine (EBM) recognizes that many
aspects of medical care depend on individual factors, which
only in part may be subject to scientific appraisal. However,
the concrete effort of applying the scientific methods of inves-
tigation to PROs in rhinitis and/or asthma clinical trials
should follow the rigorous and systematic approach of the
EBM. To ensure the best prediction of estimates, randomized
and controlled settings represent the best opportunity to eval-
uate PROs as primary outcomes.
Factors influencing PROs (e.g. alexithymia, illness percep-
tion) should to be taken into account in the inclusion and
exclusion criteria.
The methodological rigour used for traditional outcomes
measures (e.g.: biological, clinical and functional parameters)
is necessary also when assessing the PROs investigated
subjective variables.
PROs must be evaluated by validated tools exploring the
patient’s perceptions related to the outcome: each question-
naire can be demonstrated to be reliable, valid and responsive
through a rigorous validation process that consists in well-
defined steps (1, 114). The measurement characteristics are
widely accepted and considered essential for assuring that a
PRO instrument is meaningful to patients and clinicians
and provides accurate and valid assessment of the intended
outcomes (1).
If the trial is addressed to investigate the efficacy of a drug,
a double-blind randomized controlled trial is recommended.
The length of a trial is determined by the nature of the
disease (intermittent or persistent); however, the length
should also be in line with the investigated PROs. As
HRQoL tools provide information on patients’ HRQoL dur-
ing the previous 2–4 weeks, a periodical assessment of
HRQoL, respecting the tool recall period, may provide a
more comprehensive evaluation of the patients’ perspective
evaluation. According to European Medication Agency
(EMEA) recommendations for medicinal products evalua-
tion, 2- to 4-week trials for intermittent and 3- to 6-month
trials for persistent diseases are suggested (3).
In trials assessing specific effects of an intervention, the
choice of the PROs tool will depend on the expected
intervention effects. Whenever available, a specific tool for
assessing a single outcome (e.g. effect on sleep) should be
used. The choice of recall period should not only depend
on the type of tool but also on the expected time of appear-
ance of the effects of the intervention under investigation
(e.g. a shorter recall for symptomatic treatment than for
treatment aimed at modifying the natural disease history or
at reducing the disease exacerbations). A shorter recall period
is expected in symptoms evaluation rather than in HRQoL
assessment.
The presence of rhinitis in patients with asthma should be
carefully taken into account when choosing the tool/s. When
Braido et al. PROs assessment in asthma and rhinitis
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the patient has both rhinitis and asthma, a tool for the
combined HRQoL assessment of asthma and rhinitis (e.g.
RHINASTHMA) (14) should be used. Alternatively, asthma
and rhinitis should be simultaneously assessed (i.e. AQLQ,
RQLQ) (81, 93).
As of now, we lack consistent evidence that supports the
use of any PROs validated tool over another for the assess-
ment of intermittent/persistent, mild/moderate/severe rhinitis
and asthma.
As HRQoL assessment provides information on the
impact of the disease but also of its intervention upon
patient’s life, it is necessary to consider not only the func-
tional and clinical parameters but also the ongoing treatment.
The five steps for asthma classification proposed by the Glo-
bal Initiative for Asthma guidelines (42), taking into consid-
eration the therapy necessary to achieve control, seem to be
suitable. This is still missing for rhinitis (43).
In the assessment of HRQoL in intermittent/persistent,
mild/moderate/severe rhinitis and asthma, the use of specific
questionnaires should be preferred to the use of generic tools
(5, 119).
When the impact on HRQoL of a specific symptom (such
as cough) needs to be explored, disease-specific questionnaires
should be used together with a symptom-specific tool (for
instance, CCIQ, LCQ, CQLQ are specific tools for cough-
related QoL assessment) (101–103). An overview of essential
steps and issues for PROs assessment in clinical trials is
shown in Fig. 1.
• Asthma
• Rhinitis
• Asthma/rhinitis
• Primary
• Secondary
• Children
• Adolescents
• Adults
• Inclusion and 
exclusion 
criteria
• Trial design
• Choice of the 
tool 
• Scoring 
procedures
• Item dimension
• Total score
• Key messages
Select the tool 
according to the 
disease
Pros assessment as 
primary outcome is 
needed
Select the tool 
according to the age
Consider:
- Patient’s factors 
influencing PROs
- Timing of PROs 
assessment
- Availability of 
validated tools
- Scoring according 
with authors indications
- Provide complete 
results according 
with tool’s structure
- Do not combine or 
extrapolate items if 
not supported by 
validation
Conclusions do not 
have to be 
generalized to 
situations that differ 
from the one studied
Disease
Outcomes
Population
Methods
Results
Conclusion
Figure 1 Essential steps and issues for PROs assessment in clinical trials.
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Unexplored and unmet needs in PROs assessment in rhinitis
and asthma
Although PROs assessment is relevant for a more compre-
hensive description of the disease and its treatment from
patients’ perspective and some evidences have been achieved
in previous studies, the following unexplored areas should be
further investigated:
l Assessment of other PROs besides HRQoL and symp-
toms.
l Development of tools that evaluate rhinitis comorbidities
besides asthma and asthma comorbidities besides rhinitis.
l A more extensive assessment of PROs in comparison/rela-
tion with/to other clinical measures of health impact
assessment.
l A more advanced PROs assessment in paediatric age, in
particular the need for more efficacious targeted treat-
ments for those paediatric patients with severely impaired
disease and the need to demonstrate longitudinal factorial
invariance.
l A more extensive PROs assessment besides HRQoL in
caregivers/parents of rhinitic and asthmatic children.
l A rhinitis classification, taking into consideration the
therapy necessary for control achievement, needs to be
developed.
l Assessment of PROs as indicators of the effects of adap-
tation measures for modifiable risk factors (e.g. willing-
ness to pay).
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